ELOX Eloxx Pharmaceuticals, Inc.
Price Chart
Executive Summary
Eloxx Pharmaceuticals filed an 8-K detailing a 1-for-11 reverse stock split and authorized share reduction from 500M to 100M, effective May 29, 2026. The filing also reports the exchange of 2.5M common shares for pre-funded warrants by existing investors (a non-dilutive restructuring of prior warrant exercises) and the appointment of two new independent directors. The reverse split is a mechanical adjustment to maintain OTC listing compliance and does not change the company's fundamental value.
Actionable Insight
The reverse split and authorized share reduction are administrative actions to maintain OTC listing compliance and do not signal a change in business outlook. Monitor for any future capital raise or registration statement that may follow the newly authorized shelf capacity.
Key Facts
- Board approved a 1-for-11 reverse stock split effective May 29, 2026; authorized shares reduced from 500M to 100M.
- Investors exchanged 2.5M shares of common stock for pre-funded warrants to purchase an equal number of shares at $0.01 per share (non-dilutive restructuring).
- Appointed Stephen W. Webster (former CFO of Spark Therapeutics) and Nina Kjellson (General Partner at Canaan Partners) as independent directors.
- Board size reduced from six to five directors.
- Stock continues trading on OTC Pink Sheets under symbol ELOX; new CUSIP 29014R301.
Financial Impact
No new capital raised; reverse split is a mechanical share consolidation with no change to market cap. The warrant exchange is neutral — shares were already issued and simply swapped for equivalent warrants.
Risk Factors
- Reverse split may reduce liquidity and increase volatility in the near term.
- The company remains on OTC Pink Sheets, indicating continued distress or low market interest.
- No financial data or guidance provided — fundamental outlook remains unclear.
Market Snapshot
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-249692 |
| Document: d261568dex31.htm | 0001193125-26-249692 |
| Document: 0001193125-26-249692-index-headers.html | 0001193125-26-249692 |
| Document: 0001193125-26-249692-index.html | 0001193125-26-249692 |
| Document: 0001193125-26-249692.txt | 0001193125-26-249692 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
|
Jun 9, 2026
4d ago
|
EFFECT
| $6.20 awaiting T+1 | awaiting T+1 | — | $13.52 (+118.06%) |
|
Jun 4, 2026
8d ago
|
S-1/A
| $6.20 awaiting T+1 | awaiting T+1 | — | $13.52 (+118.06%) |
|
Jun 1, 2026
11d ago
|
S-1/A
| $1.51 $10.00 | ▲ +562.25% | ▲ +562.97% | $13.52 (+795.36%) |
|
Jun 1, 2026
11d ago
|
8-K
| $4.07 $1.51 | ▼ −62.90% | ▼ −63.04% | $13.52 (+232.19%) |
|
May 7, 2026
5w ago
|
S-1
| $1.43 $1.43 | ▼ −0.08% | ▼ −0.30% | $13.52 (+844.73%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access